H.C. Wainwright raised the firm’s price target on Nkarta to $22 from $10 and keeps a Buy rating on the shares. NKX019 demonstrated elimination of CD19+ cells from circulation, suggesting B cell aplasia, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NKTX: